Angioblast Systems is a biotechnology company that specializes in the development and commercialization of therapeutic products for the treatment of cardiovascular diseases. They offer a range of products including adult stem cells, protein therapeutics, gene silencing, small molecule peptides and antibodies, cytokines and antigen-receptor inhibitors, and DNAzymes. Their lead product, Revascor, is a stem cell therapy specifically designed for end-stage chronic heart failure. The company was founded in 2001 and is headquartered in New York, New York. They have a strategic alliance with Mesoblast Limited and were acquired by Mesoblast in May 2010. Angioblast Systems is focused on introducing innovative technologies like Fast Transfer, which allows immediate control of purchased domains, and building a distribution network to market their domain listings.